Claims for Patent: 8,895,777

Summary for Patent: 8,895,777

Title:	Compounds and compositions for delivering active agents
Abstract:	The present invention provides delivery agent compounds, compositions containing delivery agent compounds and an active agent and methods for delivering active agents, such as biologically or chemically active agents.
Inventor(s):	Liao; Jun (Yorktown Heights, NY), Tang; Pingwah (Elmsford, NY), Gschneidner; David (Thornwood, NY), Maeyer; Jonathan (Tucson, AZ)
Assignee:	Emisphere Technologies Inc (Roseland, NJ)
Application Number:	12/439,425
Patent Claims:	1. A delivery agent compound selected from the group consisting of: ##STR00003## and pharmaceutically acceptable salts thereof. 2. The delivery agent compound of claim 1, wherein the delivery agent is ##STR00004## or a pharmaceutically acceptable salt thereof. 3. The delivery agent compound of claim 1, wherein the delivery agent is ##STR00005## or a pharmaceutically acceptable salt thereof. 4. The delivery agent compound of claim 1, wherein the delivery agent is ##STR00006## or a pharmaceutically acceptable salt thereof. 5. The delivery agent compound of claim 1, wherein the delivery agent is ##STR00007## or a pharmaceutically acceptable salt thereof. 6. A pharmaceutical composition comprising (A) a therapeutically effective amount of a biologically active agent; (B) at least one compound selected from the group consisting of ##STR00008## and pharmaceutically acceptable salts thereof, and (C) a pharmaceutically acceptable excipient, wherein the biologically active agent is selected from BIBN-4096BS, growth hormone releasing factor, interferons, interleukin-1, interleukin-2, insulin, insulin-like growth factor (IGF), heparin, heparinoids, dermatans, chondroitins, calcitonin, erythropoietin (EPO), atrial naturetic factor, CPHPC, monoclonal antibodies, somatostatin, octreotide, adrenocorticotropin, gonadotropin releasing hormone, oxytocin, leutinizing-hormone releasing-hormone, follicle stimulating hormone, glucocerebrosidase, thrombopoeitin, filgrastim, GM-CSF5, prostaglandins, cyclosporin, vasopressin, cromolyn sodium, sodium chromoglycate, disodium chromoglycate, vancomycin, gallium nitrate, glucagon, DPP-4 inhibitors, peptide YY, desferoxamine (DFO), parathyroid hormone (PTH), glucagon-like peptide 1 (GLP-I), argatroban; and any combination thereof. 7. The pharmaceutical composition of claim 6, wherein the biologically active agent is selected from the group consisting of insulin, leutenizing-hormone releasing hormone, GLP-1, heparin, recombinant human growth hormone, argatroban, and any combination thereof. 8. The pharmaceutical composition of claim 6, wherein the biologically active agent is argatroban. 9. The pharmaceutical composition of claim 6, wherein the biologically active agent is insulin. 10. The pharmaceutical composition of claim 6, wherein the biologically active agent is human growth hormone. 11. The pharmaceutical composition of claim 6, wherein the growth hormone is human growth hormone, recombinant human growth hormone (rhGH), bovine growth hormone or porcine growth hormone. 12. The pharmaceutical composition of claim 6, wherein the calcitonin is salmon calcitonin, eel calcitonin or human calcitonin. 13. The pharmaceutical composition of claim 6, wherein the insulin is porcine insulin, bovine insulin, human insulin or human recombinant insulin. 14. The pharmaceutical composition of claim 6, wherein the heparin is unfractionated heparin, low molecular weight heparin, very low molecular weight heparin or ultra low molecular weight heparin. 15. The pharmaceutical composition of claim 6, wherein the insulin-like growth factor is IGF-I. 16. A dosage unit form comprising a pharmaceutical composition of claim 6 17. The dosage unit form of claim 16, wherein the dosage unit form is a tablet or capsule. 18. A pharmaceutical composition comprising (A) a therapeutically effective amount of a biologically active agent; (B) a compound selected from: ##STR00009## and pharmaceutically acceptable salts thereof; and (C) a pharmaceutically acceptable excipient; wherein the biologically active agent is selected from calcitonin, insulin, GLP-1, heparin, argatroban, and any combination thereof. 19. A pharmaceutical composition comprising (A) a therapeutically effective amount of a biologically active agent; (B) a compound selected from: ##STR00010## and pharmaceutically acceptable salts thereof; and (C) a pharmaceutically acceptable excipient; wherein the biologically active agent is selected from calcitonin, insulin, GLP-1, heparin, argatroban; and any combination thereof. 20. A pharmaceutical composition comprising (A) a therapeutically effective amount of a biologically active agent; (B) a compound selected from: ##STR00011## and pharmaceutically acceptable salts thereof; and (C) a pharmaceutically acceptable excipient; wherein the biologically active agent is selected from BIBN-4096BS, growth hormone releasing factor, interferons, interleukin-1, interleukin-2, insulin, insulin-like growth factor (IGF), heparin, heparinoids, dermatans, chondroitins, calcitonin, erythropoietin (EPO), atrial naturetic factor, CPHPC, monoclonal antibodies, somatostatin, octreotide, adrenocorticotropin, gonadotropin releasing hormone, oxytocin, leutinizing-hormone releasing-hormone, follicle stimulating hormone, glucocerebrosidase, thrombopoeitin, filgrastim, GM-CSF5, prostaglandins, cyclosporin, vasopressin, cromolyn sodium, sodium chromoglycate, disodium chromoglycate, vancomycin, gallium nitrate, glucagon, DPP-4 inhibitors, peptide YY, desferoxamine (DFO), parathyroid hormone (PTH), glucagon-like peptide 1 (GLP-I), argatroban; and any combination thereof. 21. A pharmaceutical composition comprising (A) a therapeutically effective amount of a biologically active agent; (B) a compound selected from: ##STR00012## and pharmaceutically acceptable salts thereof; and (C) a pharmaceutically acceptable excipient; wherein the biologically active agent is selected from BIBN-4096BS, growth hormone releasing factor, interferons, interleukin-1, interleukin-2, insulin, insulin-like growth factor (IGF), heparin, heparinoids, dermatans, chondroitins, calcitonin, erythropoietin (EPO), atrial naturetic factor, CPHPC, monoclonal antibodies, somatostatin, octreotide, adrenocorticotropin, gonadotropin releasing hormone, oxytocin, leutinizing-hormone releasing-hormone, follicle stimulating hormone, glucocerebrosidase, thrombopoeitin, filgrastim, GM-CSF5, prostaglandins, cyclosporin, vasopressin, cromolyn sodium, sodium chromoglycate, disodium chromoglycate, vancomycin, gallium nitrate, glucagon, DPP-4 inhibitors, peptide YY, desferoxamine (DFO), parathyroid hormone (PTH), glucagon-like peptide 1 (GLP-I), argatroban; and any combination thereof. 22. The composition according to claim 20, wherein the biologically active agent is selected from calcitonin, insulin, PTH, GLP-1, heparin, argatroban; and any combination thereof. 23. The composition according to claim 21, wherein the biologically active agent is selected from calcitonin, insulin, PTH, GLP-1, heparin, argatroban; and any combination thereof.

Details for Patent 8,895,777

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Eli Lilly And Company	HUMULIN R U-100	insulin human	Injection	018780	10/28/1982		2026-08-31
Eli Lilly And Company	HUMULIN R U-500	insulin human	Injection	018780	12/29/2015		2026-08-31
Eli Lilly And Company	HUMULIN R U-100	insulin human	Injection	018780	08/06/1998		2026-08-31
Eli Lilly And Company	HUMULIN R U-500	insulin human	Injection	018780	03/31/1994		2026-08-31
Eli Lilly And Company	HUMULIN R U-100	insulin human	Injection	018780	05/25/2018		2026-08-31
Amgen, Inc.	NEUPOGEN	filgrastim	Injection	103353	02/20/1991		2026-08-31